MedTrace Logo

Study To Assess Long Term Safety Of Pazopanib

NCT00387205 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2019-03-06

No results posted yet for this study

Summary

This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

Pazopanib

Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-20
Primary Completion
2013-02-13
Completion
2018-03-08

Countries

  • United States
  • France
  • Singapore
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00387205 on ClinicalTrials.gov